Details for Patent: 6,610,327
Summary for Patent: 6,610,327
| Title: | Pharmaceutical moxifloxacin preparation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Patrick Bosché, Hans Friedrich Mahler, Claus Weisemann | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Bayer Intellectual Property GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US09/830,770 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 6,610,327: Claim Scope, Expiration, Orange Book Status, and Moxifloxacin Patent LandscapeU.S. Patent No. 6,610,327 protected oral moxifloxacin formulations containing lactose, a dry binder, a disintegrant, and a lubricant. The patent also covered specified tablet compositions, film-coated tablets, wet-granulation processing, and treatment of bacterial infections using the claimed preparation. The patent was assigned to Bayer and has reached the end of its statutory patent term. It no longer creates a current U.S. blocking right against generic moxifloxacin tablets. What does U.S. Patent 6,610,327 cover?The patent covers a formulation platform rather than the moxifloxacin molecule itself. Its central limitation is a solid oral preparation containing:
The claims use the transitional term “comprises.” That wording generally makes the claims open-ended. A product can contain additional excipients and still fall within the claim if it contains every required element and satisfies the stated quantitative limitations. Claim-by-claim scope
The independent composition claim is claim 1. Claim 9 is an independent process claim, and claim 10 is an independent method-of-treatment claim. How strong is the patent estate for moxifloxacin tablets?The patent estate was commercially important during the period when Bayer’s Avelox oral tablets were protected. Its strength came from combining a common active ingredient with a defined excipient architecture and a manufacturing sequence. The central formulation is consistent with the inactive-ingredient profile used for moxifloxacin hydrochloride tablets, including lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The patent did not claim every moxifloxacin tablet. It required the lactose range and the specified functional excipient categories. Technical scope of the formulationClaim 1 reaches formulations with broad excipient identity requirements but a relatively narrow lactose range:
This structure gave the patent multiple infringement theories. A tablet could potentially infringe claim 1 without infringing claim 9 if the manufacturing process used direct compression rather than aqueous granulation. Conversely, evidence of the manufacturing process would be relevant only to process claim 9. Claim 6 is the narrowest commercial composition claimClaim 6 describes a commercially recognizable moxifloxacin tablet composition:
Because claim 6 depends on claim 1, the product must also satisfy the broader claim 1 requirements. The “up to 30%” limitation for microcrystalline cellulose does not require the presence of that excipient. Claim 3, by contrast, requires microcrystalline cellulose as the dry binder. The percentage limitations create potential design-around opportunities. A manufacturer could alter lactose concentration, replace lactose with another filler, change the disintegrant or lubricant, or use a different granulation sequence. Whether such changes avoid infringement depends on the final formulation, claim construction, and the doctrine of equivalents. What formulations are protected by U.S. Patent 6,610,327?The patent protects oral solid preparations, especially tablets, that use lactose as part of a moxifloxacin formulation containing standard tableting excipients. Protected formulation combinationsThe strongest literal-infringement scenario would involve a tablet containing:
A film-coated version would implicate claim 7. A formulation containing the claim 6 percentage ranges would present a narrower but more specific claim exposure. Formulations outside the principal claimThe following products would generally fall outside the literal scope of claim 1 if the stated facts were established:
The use of a different filler does not automatically avoid infringement if lactose remains within the claimed range. Because the claim is open-ended, additional excipients are permitted. When did U.S. Patent 6,610,327 lose exclusivity?U.S. Patent 6,610,327 issued on August 26, 2003. Its ordinary patent term ran from the relevant U.S. nonprovisional filing date, subject to any patent-term adjustment or extension recorded by the USPTO. Public patent records place the effective patent term in 2019, and the patent is no longer an enforceable blocking patent for current U.S. generic entry. [1] The patent did not provide biologic exclusivity. Moxifloxacin is a small-molecule antibacterial, and generic applicants use the abbreviated new drug application pathway rather than the biosimilar pathway. Exclusivity timeline
FDA regulatory exclusivity and patent exclusivity are separate. Any five-year new chemical entity exclusivity associated with the original moxifloxacin approval would have expired years before the formulation patent. The relevant commercial protection later depended primarily on patents and regulatory approval status rather than current FDA exclusivity. [2] What is the Orange Book status of U.S. Patent 6,610,327?The patent was associated with the U.S. moxifloxacin tablet product marketed as Avelox by Bayer. The FDA Orange Book has historically identified patent information for approved drug products, including patent listings relevant to generic applicants. [2] An Orange Book listing does not establish validity or infringement. It gives an ANDA applicant a potential basis for a Paragraph IV certification if the applicant contends that the patent is invalid, unenforceable, or not infringed. Because U.S. Patent 6,610,327 has expired, it no longer supports a current Paragraph IV-based delay of generic approval. A historical Paragraph IV challenge could have been relevant before expiration, but the patent’s expiration removed the practical value of continued enforcement. Which companies challenged moxifloxacin patent protection?Generic moxifloxacin competition involved major generic manufacturers seeking approval for moxifloxacin hydrochloride tablets. Public FDA records and patent litigation databases should be used to identify the complete set of historical Paragraph IV filers and defendants for each Avelox patent. The relevant competitive group included companies such as Teva, Sandoz, Mylan, and other ANDA sponsors active in the U.S. fluoroquinolone market. The litigation risk depended on which patent was challenged, the ANDA formulation, the certification date, and whether the brand company filed suit within the statutory 45-day period. A Paragraph IV certification would not necessarily challenge only U.S. Patent 6,610,327. Moxifloxacin applicants could also face molecule, crystalline-form, formulation, process, or method-of-use patents listed against the reference product. What patent litigation affects U.S. Patent 6,610,327?The principal legal issues for this patent would have been:
Formulation patents often face obviousness challenges based on routine selection of excipients and known tablet-manufacturing methods. The patentee’s position would depend on evidence that the particular lactose range and excipient combination produced unexpected stability, dissolution, manufacturability, bioavailability, or other technical results. Settlement agreementsA settlement involving a Paragraph IV challenge could have included a licensed entry date, a covenant not to sue, or a commercially agreed launch date. Expiration of the patent now controls the maximum exclusion period. No current market exclusion can be based solely on U.S. Patent 6,610,327. What generic entry risks exist for moxifloxacin tablets?The patent-specific risk is now low because the patent has expired. Current generic entry risks are more likely to involve:
For a historical ANDA applicant, the highest risk would have been a formulation that closely reproduced the Avelox tablet composition. A lactose-free formulation or a composition outside the claimed ranges would have reduced literal-infringement risk, although it could have introduced development or bioequivalence challenges. How does this patent compare with the moxifloxacin molecule patent?U.S. Patent 6,610,327 should be distinguished from patents claiming moxifloxacin itself or its broader pharmaceutical use.
The formulation patent was narrower than a valid compound patent. Once compound and formulation patents expired, generic manufacturers could seek approval for moxifloxacin tablets subject to FDA requirements. Does the patent create biosimilar risk?No. Moxifloxacin is a synthetic small-molecule drug, not a biologic. The relevant competitors are generic-drug applicants under the ANDA pathway, not biosimilar applicants under the Public Health Service Act. What is the geographic coverage of the patent estate?U.S. Patent 6,610,327 protected the claimed subject matter only in the United States. Corresponding applications or patents may have existed in Europe and other jurisdictions through the same international patent family, but foreign rights required separate analysis of:
U.S. expiration did not automatically terminate corresponding foreign rights. It also did not create any continuing U.S. right after expiration. Key Takeaways
FAQsIs U.S. Patent 6,610,327 a compound patent for moxifloxacin?No. It is a formulation, manufacturing-process, and treatment-method patent. It does not broadly claim the moxifloxacin molecule itself. Does a lactose-free moxifloxacin tablet infringe Patent 6,610,327?A lactose-free tablet would not literally satisfy the lactose limitation in claim 1. Separate infringement theories would require analysis of other claims and the doctrine of equivalents. Does claim 9 cover every method of making a moxifloxacin tablet?No. Claim 9 requires aqueous granulation of moxifloxacin, a dry binder, and lactose, followed by mixing the granules with a disintegrant and lubricant. Could a generic manufacturer use a different disintegrant?Yes, a different disintegrant could avoid dependent claim 4, but claim 1 still requires at least one disintegrant. The substitute must be assessed against the claim language and any equivalents theory. Can an expired formulation patent still block FDA approval?An expired patent cannot provide a current patent-based exclusion period. FDA approval may still depend on bioequivalence, manufacturing, labeling, safety, and other regulatory requirements. References
More… ↓ |
Drugs Protected by US Patent 6,610,327
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,610,327
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 198 55 758 | Nov 10, 1998 |
| PCT Information | |||
| PCT Filed | October 29, 1999 | PCT Application Number: | PCT/EP99/08230 |
| PCT Publication Date: | May 18, 2000 | PCT Publication Number: | WO00/27398 |
International Family Members for US Patent 6,610,327
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 021074 | ⤷ Start Trial | |||
| Austria | 279193 | ⤷ Start Trial | |||
| Australia | 1267400 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
